Lupin gets USFDA nod for asthmatic symptoms prevention drug
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Drug major Lupin on 25 august said it has received approval from the US health regulator for its Albuterol Sulfate Inhalation Aerosol, used for the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.

The approved product is a generic version of ProAir HFA of Teva Branded Pharmaceutical Products R&D, Inc.

In a regulatory filing, Lupin said it has received approval from the United States Food and Drug Administration (USFDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation.

Vinita Gupta, CEO, Lupin said: "The approval is timely as Albuterol MDI is a key rescue inhalation product for asthma patients who are at an increased risk of COVID-19-related complications. We look forward to launching the product this quarter and expect a steady ramp-up through the fiscal year."

Source: https://www.lupin.com/portfolio/lupin-receives-approval-for-generic-albuterol-sulphate-mdi/
Dr. Y●●h M●●●a and 5 others like this1 share
Like
Comment
Share